Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.
The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs.
For the past 35 years, Atlas Venture has operated as a diversified investor, splitting its efforts between technology and life sciences. Starting next year, the two sides will part.
European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.
A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.
BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.
The University of California has been a rich source of innovative new medicines. It's outlicensed the IP behind such standout biotechs as Aragon and Seragon--twin biotech sisters bought out by pharma giants--as well as Kite Pharma, a recent IPO success focused on CAR-T. And now it wants a bigger piece of the action.
Dow Jones writer Brian Gormley set out to find out the answer to that question, reviewing the venture data for biotech and med tech in Dow Jones' VentureSource database.